In this report, the global women health diagnostics market is segmented on the basis of application and end user. On the basis of application, the market is segmented into nine segments namely, osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound. The osteoporosis segment is further divided into bone densitometry and in vitro blood tests.
Major Growth Drivers:
Factors such as growing awareness about various health-related disorders among women, rising incidence of various chronic and lifestyle disorders in women, and high prevalence of infectious diseases such as HIV and hepatitis in women across the globe are driving the growth of the market. Moreover, the increasing adoption of point-of-care diagnostic testing and the increasing number of diagnostic and imaging centers are also expected to play a major role in market growth. However, shortage of skilled laboratory technicians and high costs of diagnostics devices, tests, and procedures are hindering the growth of women health diagnostics market.
Expected Revenue Growth:
The global women’s health diagnostics market is projected to reach USD 36.64 Billion by 2021 from USD 25.03 Billion in 2016, at a CAGR of around 7.9% during the forecast period.
Accessories to Fuel the Growth of Women’s Health Diagnostics Market :
The osteoporosis segment is further divided into bone densitometry and in vitro blood tests. The ovarian cancer segment is divided into tumor marker tests, diagnostic imaging tests and others. The cervical cancer segment is sub segmented into PAP smear testing and HPV testing. The breast cancer testing segment is further divided into mammography, tumor marker tests, blood cell count & blood chemistries, biopsies and other diagnostic imaging tests. Pregnancy and fertility testing market is sub segmented into lab-based testing, pregnancy self-test and ovulation prediction kits, ovulation prediction kits, fertility monitors and thermometers. The prenatal genetic screening & carrier testing segment is further divided into cystic fibrosis, Down syndrome and Edward syndrome, TORCH infections and others (fragile x-syndrome & tay-sachs diseases).
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901
The global market has been segmented, on the basis of applications, and end users. On the basis of application, the market is segmented into various segments, namely, osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound. On the basis of end user, the global women health diagnostics is segmented into three segments, namely, hospital and clinics, home healthcare, and diagnostic & imaging centers.
In 2015, the breast cancer testing segment accounted for the largest share of the market. However, the prenatal genetic screening and carrier testing segment is expected to grow at a higher CAGR during the forecast period. This growth can be attributed to factors such as the growing number of doctors offering genetic screening tests to pregnant women and growing awareness about these tests.
Further on, the infectious disease testing market segment is sub segmented into methicillin-resistant staphylococcus aurea (MRSA), urinary tract infections (vaginal pH & vaginitis), hepatitis, tuberculosis, and others infectious disease testing. The sexually transmitted disease testing segment comprises Chlamydia Trachomatis and Neisseria Gonorrohoeae testing, HIV testing and other STD testing.. The ultrasound segment covers breast imaging and ob/gyn imaging. On the basis of end user, the market is segmented into hospitals & clinics, home care, and diagnostic & imaging centers.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2015, North America commanded the largest share, followed by Europe, Asia-Pacific, and the RoW. Asia-Pacific represented the fastest-growing region for the women health diagnostics market during the forecast period, primarily due to improving healthcare infrastructure, growing per capita income, growing awareness among women regarding various health disorders, and rising focus of key market players on this region.
Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=128928901
Key players in the Women’s Health Diagnostics Market :
Major players in the global women’s health diagnostics market are Siemens AG (Germany), Quest Diagnostics Inc. (U.S.), Hologic, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), PerkinElmer Inc. (U.S.), Alere Inc. (U.S.), GE Healthcare (U.S.), Becton, Dickinson and Company (BD) (U.S.), Abbott Laboratories (U.S.), bioMérieux SA (France), and Koninklijke Philips N.V. (Netherlands).
According to the new market research report" Women’s Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) End User (Hospitals, Home Care) - Forecast to 2021", published by MarketsandMarkets™,The global women’s health diagnostics market is projected to reach USD 36.64 Billion by 2021 from USD 25.03 Billion in 2016, at a CAGR of around 7.9% during the forecast period.Factors such as growing awareness about various health-related disorders among women, rising incidence of various chronic and lifestyle disorders in women, and high prevalence of infectious diseases such as HIV and hepatitis in women across the globe are driving the growth of the market.Get Sample Copy for more Professional and Technical insights @ https://www.marketsandmarkets.com/Market-Reports/womens-health-diagnostics-market-128928901.htmlIn this report, the global women health diagnostics market is segmented on the basis of application and end user.
On the basis of application, the market is segmented into nine segments namely, osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound.
The osteoporosis segment is further divided into bone densitometry and in vitro blood tests.
The ovarian cancer segment is divided into tumor marker tests, diagnostic imaging tests and others.
The cervical cancer segment is sub segmented into PAP smear testing and HPV testing.Browse and in-depth TOC on "Women’s Health Diagnostics Market" 265 - Tables37 - Figures292 - PagesBrowse 265 market data tables and 37 figures spread through 292 pages and in-depth TOC on “Womens Health Diagnostics Market by application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) End User (Hospitals, Home Care) - Forecast to 2021”https://www.marketsandmarkets.com/Market-Reports/womens-health-diagnostics-market-128928901.htmlThe global women health diagnostics market is segmented on the basis of application, end user, and region.
On the basis of application, the market is segmented nine segments, namely, osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound.
Currently, the market is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe.
However, the high cost of diagnostic devices, tests, and procedures; shortage of skilled laboratory technicians; and insufficient reimbursements for diagnostic tests are expected to restrain this market’s growth to a certain extent.Market DynamicsHigh prevalence of infectious diseases in womenRising incidence of chronic and lifestyle-related disorders in womenIncreasing awareness about fertility testing in women and initiatives by government and health organizationsIncreased adoption of POC and rapid diagnostic testsGrowth in the number of private diagnostic and imaging centersPublic-private partnerships are expected to enhance infrastructure in diagnostic imaging centersBased on application, the women’s health diagnostics market is divided into nine segments—osteoporosis testing, OVC testing, cervical cancer testing, breast cancer testing, pregnancy & fertility testing, prenatal genetic screening & carrier testing, infectious disease testing, STD testing, and ultrasound tests.
The large share of this segment can be attributed to the increasing incidence of breast cancer and rising awareness about advanced breast cancer diagnostic techniques, such as ABUSGet a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901COVID-19 Impact on Global Women’s Health Diagnostics MarketSince the beginning of 2020, more and more countries across the globe shut down their borders and limited transportation and travel to contain the coronavirus (COVID-19) outbreak, thus, creating impediments for international trade and transportation.
This had disrupted the supply chains for the women’s health diagnostics market, temporarily leading to fall in demand due to uncertainty in the global economy and capital markets.
Additionally, we are estimating that the major share of the medical devices industry that includes imaging devices, and surgical products among others, which contribute 60-75% of the overall medical devices market will have a stagnant or deep fall in the growth rate in 2020 and couple of quartered from 2021.
A new, USD 5-7 billion market opportunity (by 2021) is opening up in the medical devices industry that includes critical care medical devices.In 2019, North America accounted for the largest share of the women’s health diagnostics market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
